PAX5 rearrangements (PAX5-r) act as a critical genetic driver in B-cell acute lymphoblastic leukaemia. Recent research has identified a novel in-frame PAX5 fusion in B-ALL, involving the GSE1 gene. This discovery provides fresh insights into the molecular landscape of the disease. Furthermore, it highlights new opportunities for monitoring treatment response through specialized biomarkers.

Molecular Mechanisms of the PAX5 Fusion in B-ALL

The PAX5::GSE1 fusion protein localizes directly to the cell nucleus. Once there, it actively promotes cell proliferation while suppressing the transcriptional activity of wild-type PAX5. Because of this, the fusion gene effectively disrupts normal B-cell development. Researchers also found that transcript levels of this fusion correlate significantly with treatment response. Consequently, this makes it a promising biomarker for minimal residual disease (MRD) monitoring.

Insights from the PAX5-r Signature

An analysis of 330 patients with PAX5-r B-ALL revealed 76 distinct in-frame partner genes. Although these partners vary, they induce a convergent expression profile. This profile is characterized by the dysregulation of the retinoblastoma transcriptional corepressor 1 (RB1) and p53 pathways. Additionally, many cases show a marked overexpression of nucleophosmin 1 (NPM1). These findings help clarify the core mechanisms of leukaemogenesis. Ultimately, they point toward potential therapeutic vulnerabilities in patients carrying these genetic signatures.

Frequently Asked Questions

What is the clinical significance of the PAX5::GSE1 fusion?

The PAX5::GSE1 fusion promotes leukemia cell growth and serves as a potential biomarker for monitoring minimal residual disease (MRD) and treatment response.

How does PAX5-r affect gene expression in B-ALL?

It creates a convergent profile featuring p53 and RB1 pathway dysregulation along with the overexpression of nucleophosmin 1 (NPM1).

How many PAX5 fusion partners have been identified in B-ALL?

In a large-scale study of 330 patients, researchers identified 76 distinct in-frame partner genes that fuse with PAX5.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Always seek the advice of a qualified healthcare provider for any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Wang H et al. Identification of GSE1 as a PAX5 fusion partner and characterization of PAX5 fusion signature in B-cell acute lymphoblastic leukaemia. Br J Haematol. 2026 May 27. doi: 10.1111/bjh.70578. PMID: 42204379.

2. Gu Z, Johnstone AL, Schore RJ, et al. PAX5 alterations in B-cell acute lymphoblastic leukemia. Front Oncol. 2022 Oct 25;12:1010375. doi: 10.3389/fonc.2022.1010375.

3. Liu Y et al. Recurrent PAX5::ZCCHC7 rearrangement in B-cell acute lymphoblastic leukemia. Ann Hematol. 2024 Dec;103(12):5599-5605. doi: 10.1007/s00277-024-06114-y.